<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02126137</url>
  </required_header>
  <id_info>
    <org_study_id>12-199</org_study_id>
    <secondary_id>1130357</secondary_id>
    <nct_id>NCT02126137</nct_id>
  </id_info>
  <brief_title>Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection</brief_title>
  <acronym>EZE-1</acronym>
  <official_title>A Pilot Study of the Effect of Ezetimibe in Patients With Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infection by hepatitis C virus (HCV) affects more than 170 million people in the World and
      80.000 in Chile. It causes more deaths than HIV infection in the US and is a leading cause
      for liver transplantation in Chile. Even though treatments are evolving with new direct
      antiviral agents (DAAs) that are increasing response rates, there are several issues with
      these new approaches, including increased toxicity, need for using interferon and ribavirin,
      complex algorithms of treatment, high cost, limited effectivity in certain groups (liver
      transplant patients) and drug interactions. Treatments targeted at host factors required for
      the viral cycle are becoming increasingly explored as an alternative or complement to DAAs.
      It has been recently described that Niemann-Pick C1-like 1 (NPC1L1), the intestinal receptor
      of cholesterol, serves as an entry factor for HCV. NPC1L1 is, therefore, a key transporter in
      the enterohepatic cycle of cholesterol. NPC1L1 can be blocked with ezetimibe, which is an
      approved and generally safe drug used for the management of hypercholesterolemia. Our
      hypothesis posits that blocking HCV entry to the hepatocyte or intestinal HCV reabsorption
      with ezetimibe may have an antiviral effect. In the study, we will administer ezetimibe 20
      mg/d to 20 patients with stable chronic hepatitis C for 12 weeks and assess changes in HCV
      RNA and core antigen in plasma, bile and feces.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV plasma viral load</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HCV biliary viral load</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ezetimibe administered by mouth 10 mg BID for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <arm_group_label>Ezetimibe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Chronic hepatitis C defined as detectable HCV RNA for more than 6 months.

          -  Age &gt; 18 years old.

          -  Compensated liver disease (bilirubin &lt; 3mg/dL, unless having Gilbert´s syndrome,
             albumin &gt; 3 g/dL, INR &lt; 2, no hepatic encephalopathy, no ascites or recent -1 month-
             history of variceal bleeding).

          -  HCV RNA level &gt; 10.000 IU/mL.

          -  Signed informed consent document.

        Exclusion criteria:

          -  History of cholecystectomy or known gallstones.

          -  Current HCV antiviral treatment.

          -  Medications for dyslipidemia in the preceding 2 months.

          -  Abdominal surgery that could alter biliary or intestinal anatomy.

          -  Evidence of sitosterolemia.

          -  Negative pregnancy test in urine (for females).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alejandro Soza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pilar Labbé, RN</last_name>
    <phone>+56223543820</phone>
    <email>pililabbe@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gastroenterology, Pontificia Universidad Católica de Chile</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitan</state>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Labbé, RN</last_name>
      <phone>+56223543820</phone>
      <email>pililabbe@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alejandro Soza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <link>
    <url>http://hepatitis.cl</url>
    <description>Information related to hepatitis C / Información de hepatitis por virus C (Spanish)</description>
  </link>
  <reference>
    <citation>Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med. 2012 Jan 8;18(2):281-5. doi: 10.1038/nm.2581.</citation>
    <PMID>22231557</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2014</study_first_posted>
  <last_update_submitted>November 3, 2015</last_update_submitted>
  <last_update_submitted_qc>November 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Ezetimibe</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Host</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

